Citadel Advisors
MREO

Citadel Advisors’s Mereo BioPharma MREO Stock Holding History

Citadel Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4K Sell
67,800
-549,400
-89% -$236K ﹤0.01% 12646
2025
Q4 		$257K Buy
617,200
+561,900
+1,016% +$1.07M ﹤0.01% 10480
2025
Q3 		$114K Sell
55,300
-44,500
-45% -$82K ﹤0.01% 11752
2025
Q2 		$270K Buy
99,800
+65,100
+188% +$157K ﹤0.01% 10033
2025
Q1 		$78.1K Sell
34,700
-62,600
-64% -$177K ﹤0.01% 11790
2024
Q4 		$341K Sell
97,300
-16,300
-14% -$64K ﹤0.01% 9401
2024
Q3 		$467K Buy
113,600
+13,300
+13% +$55K ﹤0.01% 8409
2024
Q2 		$361K Buy
100,300
+27,800
+38% +$90K ﹤0.01% 8744
2024
Q1 		$239K Buy
72,500
+57,100
+371% +$193K ﹤0.01% 9945
2023
Q4 		$35.6K Buy
+15,400
New +$29.5K ﹤0.01% 12111
2023
Q1 		– Sell
-88,400
Closed -$66.3K – 15193
2022
Q4 		$66.3K Sell
88,400
-18,200
-17% -$14.9K ﹤0.01% 11772
2022
Q3 		$92K Buy
106,600
+10,700
+11% +$13.1K ﹤0.01% 11164
2022
Q2 		$107K Buy
+95,900
New +$74.3K ﹤0.01% 11350
2022
Q1 		– Sell
-13,200
Closed -$21K – 14220
2021
Q4 		$21K Sell
13,200
-8,900
-40% -$17.8K ﹤0.01% 13578
2021
Q3 		$53K Sell
22,100
-12,600
-36% -$33.4K ﹤0.01% 13342
2021
Q2 		$110K Sell
34,700
-29,100
-46% -$97.6K ﹤0.01% 12834
2021
Q1 		$215K Buy
+63,800
New +$226K ﹤0.01% 11553

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors's MREO Position: Q4 2025 in Review

Citadel Advisors sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 3,171,632 shares — an estimated $6.04M sold.

Citadel Advisors first reported a position in MREO in Q3 2020 and held it in 21 quarters. The position peaked at $14.7M in Q4 2020. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Citadel Advisors reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 3,171,632 Mereo BioPharma shares in Q4 2025, an estimated $6.04M.
  • Citadel Advisors first reported a position in Mereo BioPharma in Q3 2020 and held it in 21 quarters.
  • Citadel Advisors's Mereo BioPharma position peaked at $14.7M in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.